Public Calendar: July 21-27, 2019
This public calendar is issued by the Food and Drug Administration. It lists significant meetings held by designated FDA policy makers with persons outside the executive branch of the federal government.
Official Name: Norman E. Sharpless, M.D. (Acting), Commissioner of Food and Drugs
Event Date: 07/23/2019
Location: Silver Spring, MD
Subject: Food-Related Items of Mutual Interest
FDA Participant/Group: Several FDA officials and staff
Non FDA Participant/Group: Damien O'Connor, Philip Houlding, Sean Sanlon (New Zealand Ministry of Primary Industries); Jason Frost (New Zealand Embassy); Rosemary Banks (New Zealand Ambassador to the United States of America);
Official Name: Amy Abernethy, M.D., Ph.D., Principal Deputy Commissioner
Event Date: 07/25/2019
Location: Washington, DC
Subject: Pharmaceutical Research and Manufacturers of America (PhRMA) Innovation Day 2019
FDA Participant/Group: MICHAEL FELBERBAUM; JOSEPH FRANKLIN;
Non FDA Participant/Group: Government, industry, academia and patient advocates interested in digital research and developement
No Significant Event
Official Name: Anna Abram, Deputy Commissioner for Policy, Planning, Legislation, and Analysis
No Significant Event
Official Name: Lowell J. Schiller, Principal Associate Commissioner for Policy
No Significant Event
Official Name: Mark Abdoo, Acting Deputy Commissioner for Global Regulatory Operations and Policy
No Significant Event
Official Name: Jim Sigg, Deputy Commissioner for Operations
No Significant Event
Official Name: Frank Yiannas, Deputy Commissioner for Food Policy and Response
Event Date: 07/22/2019
Location: Louisville, KY
Subject: International Association for Food Protection Annual Meeting: Keynote Address
FDA Participant/Group: N/A
Non FDA Participant/Group: Government, industry, academia and other invited guests
Event Date: 07/24/2019
Location: Silver Spring, MD
Subject: Food Safety and Supply Chain Updates
FDA Participant/Group: N/A
Non FDA Participant/Group: Carletta Ooton (Amazon.com, Inc.);
Official Name: Melinda Plaisier, Associate Commissioner for Regulatory Affairs
No Significant Event
Official Name: Mary Lou Valdez, M.S.M., Associate Commissioner for International Programs
No Significant Event
Official Name: Laura Caliguiri, Associate Commissioner for External Affairs
No Significant Event
Official Name: RADM Denise Hinton, Chief Scientist
No Significant Event
Official Name: Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research
Event Date: 07/24/2019
Location: Washington, DC
Subject: FDA Initiatives to Advance Drug Development Innovation
FDA Participant/Group: N/A
Non FDA Participant/Group: Several attendees from the National Academies of Sciences, Engineering, and Medicine Public Workshop
Official Name: Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research
Event Date: 07/24/2019
Location: Silver Spring, MD
Subject: Meeting with the I AM Amyotrophic Lateral Sclerosis (ALS) Group
FDA Participant/Group: JANET WOODCOCK;
Non FDA Participant/Group: N/A
Official Name: Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiological Health
No Significant Event
Official Name: Susan T. Mayne, Ph.D., Director, Center for Food Safety and Applied Nutrition
No Significant Event
Official Name: Mitchell R. Zeller, J.D., Director, Center for Tobacco Products
No Significant Event
Official Name: Steven Solomon, Director, Center for Veterinary Medicine
No Significant Event
Official Name: William Slikker, Jr., Ph.D., Director, National Center for Toxicological Research
Event Date: 07/23/2019
Location: Sliver Spring, MD
Subject: FDA Workshop on Biomarkers of Neurotoxicity
FDA Participant/Group: SYED IMAM;
Non FDA Participant/Group: Government, industry, academia, and other invited guests
Official Name: Stacy Cline Amin, Chief Counsel
Event Date: 07/25/2019
Location: Boston, MA
Subject: American Conference Institute: Women Leaders in Life Sciences Law and Compliance: Keynote/Fireside Chat
FDA Participant/Group: N/A
Non FDA Participant/Group: Attendees at the 2019 Women in Life Sciences Law Conference